FDA approval clears the way for a new treatment for children with Sanfilippo syndrome type A after regulators authorized a gene therapy developed to address the progressive neurodegenerative disorder. The decision marks the first time a therapy has been approved specifically for this ultra-rare condition.
The product, named Fayuvi, was developed by Ultragenyx. Company officials have not yet released pricing information. The approval follows clinical and regulatory review of data intended to show the therapy’s effect on the underlying genetic defect that causes gene therapy-amenable disease manifestations.
Sanfilippo syndrome type A is a rare inherited disorder that causes progressive cognitive decline, behavioral symptoms and early loss of function; it is sometimes described in clinical literature as resembling early-onset neurodegeneration. Cure Sanfilippo Foundation officials have said the authorization could alter the clinical outlook for affected families by providing an active treatment option where previously care focused primarily on symptom management. Cara O’Neill, the foundation’s chief science officer, has emphasized the significance of having a therapeutic pathway available at diagnosis.
The approval is a notable regulatory milestone for therapies targeting ultra-rare pediatric neurodegenerative diseases and is likely to prompt attention to practical issues that follow market entry: access for eligible patients, the cost of a one-time or infrequent genetic treatment, manufacturing scale-up and the need for continued monitoring of long-term safety and effectiveness. The FDA and the developer will outline post-authorization requirements and plans for ongoing data collection as part of implementing the new approval, while clinicians and patient groups weigh implications for care pathways and health-system readiness.
